Urinary Tract Infection Testing Market Size, Share & Trends Analysis By Type (Urethritis, Cystitis, Pyelonephritis), By End-Use (Reference Laboratories, General Practitioners, Urologists, Urgent Care), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global urinary tract infection testing market size was estimated at USD 553.91 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030. The UTI testing market is witnessing growth due to factors such as rising disease burden, rapid technological advancements, increasing geriatric population, and R&D investments by key players to introduce self-testing products.Urinary tract infection is becoming a common global concern. According to research studies, UTI occurs in one in five adult women at some point in their life. In the U.S., about 25%-40% of women aged 20-40 have suffered a UTI. More than 6 million UTI patient visits physicians every year in the U.S. Out of which around 20% of those visits are to the emergency department.

Women are more prone to UTIs than men.The incidence of disease in adult women tends to increase with age. The infection rate is comparatively high in postmenopausal women, owing to factors such as changes in vaginal flora, which provides a favorable environment for the growth of certain pathogens.

The introduction of portable handheld equipment and the availability of at-home sample collection kits & self-testing kits for UTI testing are among the factors likely to boost adoption. For instance, in May 2020, Healthy.io Ltd. launched a home test kit in the UK. Moreover, point-of-care testing for UTIs will be a key growth area, which is expected to increase investments by companies. Moreover, researchers are developing technologically advanced products for disease diagnosis, which are expected to be commercialized in space in the coming years. In January 2020, engineers at the University of Bath developed a test for UTIs using a smartphone camera. They have claimed that it can detect E.coli presence in a urine sample in less than 25 minutes.

The space experienced a setback due to the COVID-19 pandemic. Amid the pandemic, hospitals and clinics have reported a decrease in the number of urinary tract infection testing. However, in several countries globally, the effect of COVID-19 declined to post the second quarter of 2021, which helped the market regain traction.

However, false results associated with UTI testing may hamper space growth. According to a research article published by CUTIC, rapid tests or dipstick tests can give false-positive results in one out of five patients. Such factors can hamper their reliability, slowing down space growth. In addition, an advanced automated system can also provide false results. Nevertheless, the rate of false results is relatively very less in the case of an advanced system.

By Type Insights

The cystitis segment dominated the market in 2021. This can be attributed to the high incidence & recurrence rate of cystitis, increased number of product approvals, and the high number of diabetes patients who are more prone to cystitis. According to NCBI’s epidemiology report, globally, acute cystitis occurs in about 10 out of 100 women every year. In addition, its recurrence rate is also high in women; half of the women affected by cystitis have it again within a year.

In addition, pyelonephritis is anticipated to be the fastest-growing segment in the coming years and is expected to grow at a CAGR of 4.0%. due to its growing prevalence.According to NCBI statistics, in the U.S., more than 250,000 cases of pyelonephritis are diagnosed every year. The study further suggested that across the globe, in women aged 18 years to 49 years, there are around 28 pyelonephritis cases per 10,000 individuals.

By End-Use Insights

The general practitioner segment held a share of 13.27% in 2021. This can be attributed to the fact that it is the primary point of contact for most patients with urinary tract infection, and in most cases, uncomplicated UTIs is diagnosed and treated by a general practitioner.According to an American Urological Association article, in the U.S., every year, UTIs contribute to more than 8 to 10 million doctor visits.

The reference laboratories segment is expected to grow at a CAGR of 3.6% due to ongoing efforts to improve patient outcomes by providing diagnostic facilities. In addition, reference labs can handle large volumes of diagnostic tests at an expedited rate and provide better results at comparatively lower prices, which is anticipated to offer economies of scale to service providers.

Regional Insights

In 2021, North America dominated the overall UTI testing market in terms of value, accounting for a share of nearly 34.16%. This can be attributed tothe high disease burden, availability of infrastructure, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, rise in patient awareness, and presence of major players.

In addition, the Asia Pacific region is expected to witness the highest CAGR during the forecast period. The high growth rate can be attributed to the rising disease incidence rate and the high geriatric population. Increasing demand for cost-effective diagnostics and a growing population are among the factors significantly contributing to market growth. Asia Pacific markets such as Australia and South Korea already have a healthcare reimbursement system that provides coverage for UTI diagnostic tests.

Key Companies & Market Share Insights

The global UTI testing market is highly competitive, led by companies such as F. Hoffmann-La Roche Ltd. and Sysmex Corporation. Key players are trying to gain market share through product launches and other strategic initiatives. For instance, in July 2020, Uqora, Inc. (Pharmavite, LLC), a urinary health biotechnology company, launched a UTI diagnostic and management kit. It includes the rapid diagnostic device, Clarify, which is compatible with PoC and homecare settings. Similarly, in May 2020, Healthy.io Ltd. launched a urinary tract infection rapid home test kit in the UK. Some of the prominent key players in the global UTI testing market include:

• QIAGEN

• Accelerate Diagnostics, Inc.

• Bio-Rad Laboratories, Inc.

• F. Hoffmann-La Roche Ltd.

• Danaher Corporation

• Siemens Healthcare GmbH

• Randox Laboratories Ltd.

• Thermo Fisher Scientific, Inc.

• bioMérieux SA

• T2 Biosystems, Inc.

Urinary Tract Infection Testing Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the Urinary Tract Infection testing market based on type, end-use, and regions.

• Type Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Urethritis

  • Cystitis

  • Pyelonephritis

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • General practitioners (GPs)

  • Urologists

  • Urogynecologists

  • Hospital Laboratories

  • Reference Laboratories

  • Hospital Emergency Departments

  • Urgent Care

  • Others

• Regional Outlook (Revenue, USD Million, Volume, Units, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE